Unlike Samsung's Ballie or Amazon's Astro robot, the FollowMe isn't an anthropomorphic display but a literal TV on wheels.
About one in eight Americans have tried GLP-1 drugs like Mounjaro, Zepbound and Ozempic — and they’ve shrunken appetites so ...
As the United States approaches 2026, key structural shifts in retirement and healthcare financing are poised to affect how ...
As the year comes to a close, it's time to look back at the numerous innovations across the diabetes technology industry in ...
Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on ...
Rarer diabetes patients in Singapore can now receive up to 80% government subsidies for continuous glucose monitoring (CGM) ...
Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy ...
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. The company said its Smart Basal ...
New RAMQ coverage means eligible Québec residents with type 2 diabetes on intensive insulin therapy can now access Dexcom Continuous Glucose Monitoring (CGM) to simplify diabetes management. Dexcom, ...
DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...
Google may not use a Samsung modem for its next chip. A rumor suggests that the tech giant may pick MediaTek’s M90 modem instead. The reason may be that the M90 modem is faster and more energy ...